Saltar al contenido principal
Elsevier

Anti-Prostate Cancer Agents

  • 1 Edición - 23 de mayo de 2025
  • Última edición
  • Autor: Qiao-Hong Chen
  • Idioma: Inglés

Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book… Leer más

Descripción

Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents.

This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.

Puntos claves

  • Provides insight on how the design and discovery process of anti-prostate cancer agents have evolved
  • Explore the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications
  • Highlight the molecular targets and mechanism of action for anti-prostate cancer agents

De interès para

Graduate students and researchers working on drug discovery and development, Medicinal Chemistry, Bioorganic Chemistry, Chemical Biology, and Biomedical Science

Índice

1. Introduction: Overview of Prostate Cancer     

2. Why has one got prostate cancer?

3. Androgen Deprivation Therapy

4. Anti-prostate cancer agents interacting with topoisomerase

5. Microtubule-Stabilizing Compounds as Anti-Prostate Cancer Agents

6. Androgen/Androgen Receptor Signaling Pathway and Prostate Cancer 

7. Anti-Prostate Cancer Agents Suppressing Androgen Biosynthesis 

8. First Generation Nonsteroidal Androgen Receptor Antagonists 

9. Second Generation Nonsteroidal Androgen Receptor Antagonists

10. Anti-Prostate Cancer Agents Interacting with N-Terminal Domain of Androgen Receptor

11. Androgen Receptor Degraders as Anti-Prostate Cancer Agents

12. Radiotherapeutics for treatment of Prostate Cancer

13. Immunotherapy for Prostate Cancer

14. Radiosensitizer for prostate cancer 

15. Anti-Prostate Cancer Agents Targeting Prostate-Specific Membrane Antigen

16. Anti-Prostate Cancer Agents Targeting Poly(ADP-Ribose)Polymerase

17. Combined Anti-Prostate Cancer Agents

18. Future Directions

Detalles del producto

  • Edición: 1
  • Última edición
  • Publicado: 25 de julio de 2025
  • Idioma: Inglés

Sobre el autor

QC

Qiao-Hong Chen

Dr Qiao-Hong Chen received her PhD degree in Medicinal Chemistry from Sichuan University, China. Appointed as a Lecturer in 2001, She was promoted to the position of Full Professor in 2003 at Sichuan University. She was a Postdoctoral Fellow for three years at the University of Alberta in Canada and a Senior Research Fellow for six years at Virginia Tech. She joined Fresno State in 2012. Her research interests focus on natural products-based anticancer agents. She has published 152 peer-reviewed scientific publications, as well as 5 book chapters.
Afiliaciones y experiencia
Professor and Graduate Coordinator, Department of Chemistry and Biochemistry, California State University, California, USA

Ver libro en ScienceDirect

Lee Anti-Prostate Cancer Agents en ScienceDirect